Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and pote...
Reached a long-term business cooperation with a large pharmaceutical company to help it promote production licensing and commercial supervision and app...
BW-41012 represents the eighth clinical candidate from Argo's innovative RNAi pipeline, and is being evaluated for the prevention of thromboembolic disea...
Aims to Raise Capital to Fund Global Clinical Studies for LNP7457 (PRMT5) & LNP8701 (SOS1) Global pharmaceutical leader Lupin Limited &n...
Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding ...
Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, annou...
Parse Biosciences, a QIAGEN company, and the leader in scalable and accessible single cell sequencing, today announced that the Genomics Platform Core Fa...
GEM Global Yield LLC SCS ("GEM") has executed a Share Purchase Agreement (the "SPA") with the existing shareholders of Taiwan-listed Senhwa Biosciences Inc...
ASC48 is a potentially first-in-class oral small molecule GIPR agonist. - ASC48 demonstrated an EC50 of 1 pM in the hGIPR cAMP activation assay, exhibit...
SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing...
Biocytogen and Whitehawk Therapeutics, Inc. announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytog...
Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform huma...
TaiMed Biologics (TPEX: 4147) announced that its HIV therapy Trogarzo (ibalizumab; English name: Trogarzo Injection; Chinese name: 佐加洛注射劑) ha...
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapie...
© 2026 Biopharma Boardroom. All Rights Reserved.
